Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer
Year: 2026
Type: article
Abstract: Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive phenotype and the scarcity of druggable targets. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a critical driver of TNBC progression, yet its has precluded the development of conventional occupancy-driven inhibitors. In this study, we employed an event-driven proteolysis-targeting chimera (PROTAC) strategy to target this “undruggable” LRG1 for degradation. Leveraging our previously developed ETTAC-2─a peptide-based PROTAC with established efficacy in ocular neovascularization and renal fibrosis models─we demonstrate that this degrader induces effective LRG1 degradation via the ubiquitin-proteasome system in a dose- and time-dependent manner in 4T1 TNBC cells. Mechanistically, ETTAC-2-mediated degradation of LRG1 suppressed the p-AKT and HIF-1α signaling axes, impairing cell proliferation in vitro and orchestrating a robust antitumor response in vivo. Systemic administration of ETTAC-2 significantly attenuated mammary tumor growth and impeded the aggressive phenotype by reversing the epithelial-mesenchymal transition (EMT) program through sustained inhibition of HIF-1α signaling. By effectively reversing EMT markers and curtailing the malignant progression of TNBC without observable systemic toxicity, our findings validate LRG1 as a viable therapeutic target and establish ETTAC-2 as a pioneering lead compound that bypasses structural limitations to treat recalcitrant breast cancers.
Source: ACS Omega
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,935
Award: G2678475770
OpenAlex ID: W7225912441
